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Abstract
The advent of microarray technology has made it possible to classify disease states based on gene expression profiles of
patients. Typically, marker genes are selected by measuring the power of their expression profiles to discriminate among
patients of different disease states. However, expression-based classification can be challenging in complex diseases due to
factors such as cellular heterogeneity within a tissue sample and genetic heterogeneity across patients. A promising
technique for coping with these challenges is to incorporate pathway information into the disease classification procedure
in order to classify disease based on the activity of entire signaling pathways or protein complexes rather than on the
expression levels of individual genes or proteins. We propose a new classification method based on pathway activities
inferred for each patient. For each pathway, an activity level is summarized from the gene expression levels of its condition-
responsive genes (CORGs), defined as the subset of genes in the pathway whose combined expression delivers optimal
discriminative power for the disease phenotype. We show that classifiers using pathway activity achieve better performance
than classifiers based on individual gene expression, for both simple and complex case-control studies including
differentiation of perturbed from non-perturbed cells and subtyping of several different kinds of cancer. Moreover, the new
method outperforms several previous approaches that use a static (i.e., non-conditional) definition of pathways. Within a
pathway, the identified CORGs may facilitate the development of better diagnostic markers and the discovery of core
alterations in human disease.
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Introduction
Analysis of genome-wide expression profiles has become a
widespread technique for identifying diagnostic markers of various
disease states, outcomes, or responses to treatment [1–5]. Markers
are selected by scoring each individual gene for how well its
expression pattern can discriminate between different classes of
disease or between cases and controls. The disease status of new
patients is predicted using classifiers tuned to the expression levels
of the marker genes.
One challenge of expression-based classification is that cellular
heterogeneity within tissues and genetic heterogeneity across
patients in complex diseases may weaken the discriminative power
of individual genes [6–9]. In addition, marker genes are typically
selected independently although proteins are known to function
coordinately within protein complexes, signaling cascades, and
higher-order cellular processes. Thus, the resulting expression-
based classifiers may contain unnecessarily many marker genes
with redundant information which may lead to decreased
classification performance [10].
Due to these types of difficulties, several groups have
hypothesized that a more effective means of marker identification
may be to combine gene expression measurements over groups of
genes that fall within common pathways [11–17]. The pre-defined
functional groupings of genes are drawn from canonical pathways
curated from literature resources such as the Gene Ontology [18]
and KEGG databases [19] or experimentally defined gene lists
from microarray studies [15,16,20]. Recently, pathway-based
analysis has been extended to perform disease classification of
expression profiles. Some approaches use gene expression
parametrically by representing pathway activity with a function
summarizing the expression values of member genes [21,22], while
others estimate probabilities of pathway activation based on the
consistency of changes in gene expression [23,24]. Alternative
approaches engineer normal cells to activate pre-selected onco-
genic pathways to determine gene signatures which can distinguish
tumor characteristics [20,25]. These methods have demonstrated
classification accuracies that are comparable to conventional gene-
based classifiers, while providing a strong biological interpretation
for why the expression profile is associated with a particular type of
disease (i.e., based on the pathways found to be perturbed). On the
other hand, a potential shortcoming of current pathway-based
classifiers is that the pre-defined set of genes making up a pathway
may be derived from conditions irrelevant to the disease of
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pathway are typically altered at the mRNA level.
Here, we propose a novel gene-expression-based diagnostic that
incorporates pathway information in a condition-specific manner
(Pathway Activity inference using Condition-responsive genes,
PAC). The markers are encoded not as individual genes, nor as
static literature-curated pathways, but as subsets of condition-
responsive co-functional genes (Condition-Responsive Genes,
CORGs). To optimally discriminate samples of different pheno-
types, we identify CORGs from each static pathway in the context
of the specific disease in question. The combined expression levels
of the CORGs are treated as the pathway ‘‘activity’’ and used to
build classifiers for predicting the disease status of new patients.
We show that our pathway-based approach outperforms previous
analyses of differential expression in classifying samples across
seven different datasets. Moreover, we show that pathway
activities inferred using only CORGs lead to better classification
performance as compared to pathway activities inferred using
various types of summary statistics of all genes which participate in
a common pathway. The resulting pathway markers and their
CORGs also provide models of the molecular mechanisms which
define the disease of interest.
Methods
Datasets
We obtained previously published mRNA expression datasets
covering seven different disease classification scenarios: 24
expression profiles of HeLa cells after stimulation by Tumor
Necrosis Factor (TNF) [26], expression profiles of 62 primary
prostate tumors and 41 normal prostate specimen [27], expression
profiles of 143 acute lymphoblastic leukemia (ALL) patients [28],
breast cancer expression profiles for 295 patients from the
Netherlands [29] and 286 patients from the USA [5], and lung
cancer expression profiles for 86 patients from Michigan [30] and
62 patients from Boston [31].
Each dataset was divided into two populations of distinct
phenotypes as per the original publications (Table S1). For the
TNF study [26], 12 samples had normal IkB proteins (labeled
‘‘Wildtype’’) and 12 samples expressed mutant IkB blocking NF-
kB signaling (labeled ‘‘Mutant’’). For the prostate cancer study
[27], 62 samples were retrieved from primary tumors (labeled
‘‘Cancer’’) and 41 samples were from normal prostate specimen
(labeled ‘‘Normal’’). For the ALL study [28], 79 patients suffered
from one subtype resulting from a t(12;21)(p12,q22) reciprocal
translocation (labeled ‘‘TEL-AML1’’) and the other 64 patients
showed hyperdiploid hyperdip .50 (labeled ‘‘HH’’). For the two
breast cancer datasets, metastasis had been detected in 78 [29] and
106 [5] patients during follow-up visits within five and seven years
after surgery (labeled ‘‘Metastatic’’); the remaining 217 and 180
patients were still metastasis free (labeled ‘‘Non-metastatic’’). For
the two lung cancer datasets, we defined the two phenotype
populations according to Subramanian et al. [15], who labeled 24
patients in the Michigan dataset and 31 patients in the Boston
dataset as having a ‘‘Poor’’ prognosis, while the remaining 62 and
31 patients were labeled as having a ‘‘Good’’ prognosis.
For pathway information, we used the C2 functional set
downloaded from MsigDB v1.0 [15]. This set includes 472
canonical metabolic and signaling pathways pooled from eight
manually curated databases along with 50 co-expressed gene
clusters obtained from various microarray studies. Each pathway
or gene cluster defines a set of genes (gene clusters are henceforth
also called ‘‘pathways’’). In total, the available pathways covered
5602 genes, most but not all of which were measured in the seven
gene expression datasets, due to the various array platforms used.
Condition-Responsive Gene Identification and Pathway
Activity Inference
To integrate the expression and pathway datasets, we overlaid
the expression values of each gene on its corresponding protein in
each pathway. Within each pathway, we searched for a subset of
member genes whose combined expression levels across the
samples were highly discriminative of the phenotypes of interest
(Figure 1). For a particular gene set G, let a represent its vector of
activity scores over the samples in a study, and let c represent the
corresponding vector of class labels (e.g. good vs. poor prognosis).
To derive a, expression values gij are normalized to z-transformed
scores zij which for each gene i have mean mi=0 and standard
deviation si=1 over all samples j. The individual zij of each
member gene in the gene set are averaged into a combined z-score
which is designated the activity aj (the square root of the number
of member genes is used in the denominator to stabilize the
variance of the mean). Many types of statistic, such as the
Wilcoxon score or Pearson correlation, could be used to score the
relationship between a and c. In this study, we defined the
discriminative score S(G) as the t-test statistic [32] derived on a
between groups of samples defined by c.
For a given pathway, a greedy search was performed to identify
a subset of member genes in the pathway for which S(G) was
locally maximal. We refer to this subset as the set of ‘‘condition-
responsive genes’’ (CORGs) representing the majority of the
pathway activation under the relevant conditions. To identify the
CORG set, member genes were first ranked by their t-test scores,
in ascending order if the average t-score among all member genes
was negative, and in descending order otherwise. The CORG set
G was initialized to contain only the top member gene and
iteratively expanded. At each iteration, addition of the gene with
the next best t-test score was considered, and the search was
terminated when no addition increased the discriminative score
Author Summary
The advent of microarray technology has drawn immense
interest to identify gene expression levels that can serve as
biomarkers for disease. Marker genes are selected by
examining each individual gene to see how well its
expression level discriminates different disease types. In
complex diseases such as cancer, good marker genes can
be hard to find due to cellular heterogeneity within the
tissue and genetic heterogeneity across patients. A
promising technique for addressing these challenges is
to incorporate biological pathway information into the
marker identification procedure, permitting disease classi-
fication based on the activity of entire pathways rather
than simply on the expression levels of individual genes.
However, previous pathway-based methods have not
significantly outperformed gene-based methods. Here,
we propose a new pathway-based classification procedure
in which markers are encoded not as individual genes, nor
as the set of genes making up a known pathway, but as
subsets of ‘‘condition-responsive genes (CORGs)’’ within
those pathways. Using expression profiles from seven
different microarray studies, we show that the accuracy of
this method is significantly better than both the conven-
tional gene- and pathway- based diagnostics. Furthermore,
the identified CORGs may facilitate the development of
effective diagnostic markers and the discovery of molec-
ular mechanisms underlying disease.
Pathway-Based Disease Classification
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the pathway activity across the samples.
Previous Gene-Set Ranking Approaches and Other
Pathway-Based Classification Methods
We also used a method proposed by Tian et al. [16] to assess the
probability of a pathway being altered in disease based on the
correlation between the expression of all its member genes and the
disease phenotype. For each pathway P in MsigDB, Tian et al.
calculated a score T by averaging the t-test statistic scores of all
member genes. Higher T was indicative of stronger pathway
correlation with the disease status. The top 10% of pathways (52
pathways) in each dataset were selected for further analysis and for
classification. The decision of whether a pathway had been
disrupted by disease was assessed on the basis of the discriminating
power of the member genes between the classes of interest (using a
t-test statistic). However, there may be some signatures of pathway
disruption that are independent of the classification task at hand.
To detect such signatures, a number of statistical functions [8,33]
can be adopted in the framework of Tian et al. Unlike the t-test,
these functions are designed to detect perturbed patterns rather
than mean expression changes.
To compare our PAC with other activity inference schemes, we
implemented three other expression summarization methods,
including a principal component analysis (PCA) similar to that
used in Bild et al. [20] and the mean and median approaches used
in Guo et al. [22]. Bild et al. used the first principal component of
the expression of the member genes to represent the activation of a
given pathway, while Guo et al. summarized the expression levels
of member genes by using simple statistics like mean and median.
Marker Robustness Evaluation
For each dataset, 100 alternative two-fold splits were generated
of each mRNA expression profile in the dataset. Pathways were
Figure 1. A schematic diagram of key gene identification and activity inference. Selected significant pathways are further subject to CORG
identification corresponding to the phenotype of interest. Gene expression profiles of patient samples drawn from each subtype of diseases (e.g.,
good or poor prognosis) are transformed into a ‘‘pathway activity matrix’’. For a given pathway, the activity is a combined z-score derived from the
expression of its individual key genes. After overlaying the expression vector of each gene on its corresponding protein in the pathway, key genes
which yield most discriminative activities are found via a greedy search based on their individual power (see Methods). The pathway activity matrix is
then used to train a classifier.
doi:10.1371/journal.pcbi.1000217.g001
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CORGs for each pathway were identified using the samples in a
single fold. Individual genes were also ranked by their discrimi-
native power on each fold. The robustness was estimated as the
average degree of overlap among top pathways/genes derived
from the two folds of samples across the 100 splits.
Classification Evaluation
Logistic regression models [34] were trained on both the
pathway activity matrix (pathways versus samples) and the original
gene expression matrix (genes versus samples—i.e., conventional
gene-based classification). For within-dataset experiments, the
expression samples in a dataset were divided so that four-fifths of
the samples were used as the training set to build the classifier, and
one fifth were used as the test set (five-fold cross validation). Each
of the five subsets in the dataset was evaluated in turn as the test set
and withheld during marker selection (including CORG identifi-
cation) and classifier training. In order to train a generalized
classifier and to minimize over-fitting, we further split the training
set into three smaller subsets of equal size: two subsets were used as
the marker selection set to rank markers (pathways or genes) as
well as identify CORGs (pathways only), and one subset was used
as the validation set for assessing which marker set was significant
for classification. Thus the CORGs might be different for a
specific pathway, depending on the samples used in the marker
selection set. Pathways or genes were ranked by the p-value of
discriminative power to classify samples in the marker selection set,
after which the logistic regression model was built by adding
markers sequentially in increasing order of p-value (sequential
selection). The number of markers used in the classifier was
optimized by evaluating its Area Under ROC Curve (AUC, see
[35] for details) on the validation set. The AUC metric captured
performance over the entire range of sensitivity/specificity values.
The final classification performance was reported as the AUC on
the test set using the classifier optimized from the validation set.
For unbiased evaluation, we generated 100 alternative five-fold
splits of samples in each dataset and ran cross validation on each
split. The final reported AUC values were averaged across 500
randomly selected ways of partitioning the data into four-fifths
training and one-fifth test samples.
For cross-dataset experiments, markers (pathways or genes)
were selected using the whole first dataset and then tested on the
second dataset (or vice versa). CORG identification was also
performed on the first dataset. As for the within-dataset
experiments, the patient samples in the second dataset were
divided into five subsets of equal size: four subsets were designated
as the ‘‘training’’ set to build the classifier using markers from the
first dataset, and one subset was held for testing. One hundred
alternative five-fold splits were generated to partition samples in
the second dataset into four-fifths for training and one-fifth for
testing. Therefore, we learned 500 classifiers for each of these two
datasets, in which each classifier was associated with its own
pathway marker set. The averaged AUC values among the 500
classifiers built on the second dataset were reported as the final
classification performance for each marker set identified from the
first dataset. Among the 500 classifiers, the pathway marker set
used in classification could be different depending on which
training samples were used in the second dataset. However, the
CORGs of each pathway were the same across these 500 classifiers
because the identification was done using the whole first dataset.
In this study, for pathway-based classifiers, the input marker set
was defined as the top 10% of pathways in MSigDB ranked by
Tian et al. [16] using a designated training set. In order to
compare pathway and gene based methods in a fair manner that
controls for the number of genes used, we provided the gene-based
classifiers with the same number of top ranked genes as the
number of CORGs pooled from the significant pathways selected
by Tian et al. [16].
Results/Discussion
Pathway Markers Amplify Signals over Multiple Weak
Gene Markers
We first tested the robustness of the pathway markers selected
by the method of Tian et al. [16]. The agreement between the
significant pathways was higher than that between the individually
scored gene markers (Figure S1). The CORGs within the top
pathways were also more consistent than individually scored gene
markers in different subsets of samples. The observed robustness of
CORGs might imply that some non-differentially expressed genes,
which are often dropped in conventional analysis, do have
associations with the disease of interest.
We hypothesized that pathway information could be used to
restrict the search space for truly perturbed genes whose
aggregated expression is more predictive for disease status than
individually considered. We began by analyzing the breast and
lung cancer datasets (four datasets in total), since each dataset has
available two separate cohorts of patients studied by different
researchers. The top 10% of pathways were selected for each of
the four datasets (see Methods). We identified the CORGs for each
top pathway and aggregated their expression levels into a single
activity value for each sample (Methods). By design, the inferred
pathway activities had more discriminative power in distinguishing
samples with different disease phenotypes than did the individual
expression levels of the member CORGs (PAC versus CORGs in
Figure 2A, 2C, 2E, and 2G). However, the discriminative power
fell when the pathway activity was inferred using not only the
CORGs but all member genes associated with each pathway
(PAC_all in Figure 2A, 2C, 2E, and 2G). This result suggests that,
as might be expected, not all genes in a significant pathway are
transcriptionally altered or associated with the phenotype of
interest.
We then compared our pathway markers to the individual gene
markers selected without pathway information. We found that the
PAC activity scores outperformed individual gene markers in
terms of discriminating samples with different disease phenotypes
in both the source datasets used for marker identification (PAC
versus Genes in Figure 2A, 2C, 2E, and 2G) and the independent
verification datasets (Figure 2B, 2D, 2F, and 2H). In the
verification datasets, the CORGs demonstrated almost the same
discriminative power as did the top genes, although the top genes
were more powerful in the original datasets. These comparisons
suggest that aggregating the perturbed genes in a pathway leads to
a better marker for discriminating disease phenotypes. Although
the expression of a single gene might not be a strong predictor,
pathway integration provides a means to amplify individual weak
signals at the transcriptional level.
Pathway Markers Increase the Classification Accuracy
We next tested that the inferred pathway activity levels could be
used in the classification of disease status for a new expression
profile. To use pathway information for classification, pathway
activities were used as feature values in a classifier based on logistic
regression. The technique of five-fold cross validation was applied
to test the predictive power of the pathway markers (see Methods).
In each run of cross validation, we only considered the top 10% of
pathway markers selected by Tian et al. [16] using the designated
training data.
Pathway-Based Disease Classification
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phenotypes were compared between four marker sets in the source dataset, which was used to identify markers—(A) and (C) for the two breast
cancer datasets and (E) and (G) for the two lung cancer datasets—or in an independent verification dataset—(B) (D) (F) (H). Pathway markers were
ranked by using their absolute t-scores from a two-tail t-test on activity levels (see S(G) in Methods) between the two phenotypes of interest in the
source dataset, and their discriminative power in the same order was measured in the verification dataset. Pathway activities were estimated using
only CORGs (PAC) or all member genes (PAC_all). The individual predictive power of CORGs in the top pathways was also evaluated using the same t-
test on their gene expression levels (CORGs). A similar analysis was performed using the same number of top discriminative genes as the number of
CORGs covered by the pathway markers (Genes).
doi:10.1371/journal.pcbi.1000217.g002
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significantly outperformed the conventional gene-based classifiers
(Gene). The improved performance was not simply due to
grouping multiple gene expression measurements, as shown by
comparing our performance with that of random groups of genes
(PAC_random; averaged AUCs of 1000 sets of same-size random
gene sets as the significant pathways). Classifiers using pathway
activity inferred by the mean or median of the member gene
expression [22] or the 1
st principle component (PCA) [20] had
higher predictive power than those using random gene sets
(PAC_random), but only comparable power to the conventional
gene-based classifiers. These results indicate that there are at least
two critical factors in developing an advanced molecular
diagnostic: (1) a biologically meaningful definition of pathways
and (2) inference of condition-specific pathway activity.
Next, we tested the reproducibility of the pathway markers
selected across different microarray platforms or different cohorts
of patients. For this purpose, we used expression profiles of the two
lung cancer datasets and the two breast cancer datasets generated
from different groups. For each cancer, significant pathways and
their CORGs were identified using the whole first dataset and then
tested on the second dataset, or vice versa (Figure 3B). Our
pathway-based classifiers again significantly outperformed the
gene-based classifiers.
To show that the better performance of PAC was not dependent
on the chosen classification algorithm, we evaluated all markers
and pathway activity inference methods using three additional
classification approaches: k-nearest neighbors, naı ¨ve Bayes, and
linear discriminative analysis. Moreover, forward selection method
was also employed to show our superior performance was not
beneficial from the feature selection method used. All further
analyses demonstrated the same trends, i.e., our CORG-based
pathway classifiers outperformed other gene-based and pathway-
based classifiers (Figures S2 and S3).
Pathway Markers and Their CORGs Provide Biologically
Informative Models for Lung Cancer Prognosis
Beyond achieving better classification performance, the dis-
criminative pathway markers and their CORGs can lend insight
into the biological basis for why samples are classified as a specific
disease status. As an example, we examined the pathway markers
selected in the above two cross-dataset experiments for classifica-
tion of lung cancer prognosis (for a similar analysis of breast cancer
metastasis, see Table S2 and Figure S4). We counted the
frequency with which each pathway in MSigDB was selected
over the 500 classifiers, and we identified the top most frequent
pathways having over 100 occurrences (Table 1).
Pathways involved in glucose metabolism (‘‘Glycolysis’’ in
Table 1) and estrogen signaling (‘‘Breast cancer estrogen
signaling’’ and ‘‘Estrogen receptor modulators down-regulated
genes’’) were frequently used in classifying lung cancer patients,
and over-expression of these pathways had poor prognosis in both
datasets (Figure 4). Constitutively up-regulated glycolysis has been
observed in most primary and metastatic cancers and further
explored to develop potential therapeutic targets [36–38]. Up-
regulated glycolysis enables unconstrained proliferation and
invasion and may lead to a more aggressive type of lung cancer
[37]. Estrogen signaling has been known to promote cell
proliferation and suppresses apoptosis, and its role in the late
steps of lung metastasis has recently been suggested [39]. As shown
in Table 1, many pathways could be represented by CORGs of
the size from two to four, although some required more than eight
genes (Figure S5). Especially for larger CORG sets, it would be
computationally infeasible to identify these combinations to have
Figure 3. Classification accuracy within (A) and across (B) datasets. Bar chart of Area Under ROC Curve (AUC) classification performance of
CORG-based pathway markers (PAC), conventional pathway markers (Mean, Median, and PCA), and individual genes (Gene; same number of top
discriminative genes as the number of CORGs in pathway markers). Classification performance is summarized as mean6ste of AUC over 100 runs of 5-
fold cross-validation within a dataset. To compute PAC_random, the AUC values of 1000 sets of random gene sets were averaged. Numbers above
the red bars are -log (p-value) from the Wilcoxon signed-rank test on the 500 AUCs of ‘‘PAC’’ against those of ‘‘Gene’’ (only the ones with p-
value,0.05 are shown). The p-values measure the significance of difference between PAC and gene-based classification.
doi:10.1371/journal.pcbi.1000217.g003
Pathway-Based Disease Classification
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knowledge.
Conclusion
We have demonstrated that effectively incorporating pathway
information into expression-based disease diagnosis can provide
better discriminative and more biologically defensible models.
Grouping gene expression responses via functional linkages can
amplify individually weak signals due to the heterogeneity of
samples, either genetic or technical. In addition, such gene
groupings also emerge as a critical step of removing potential
redundancy on expression among genes associated with the same
function. In view of classification tasks, genes of the same
expression pattern do not provide extra information for a classifier
but may cause over-fitting. The identification of condition-
responsive genes within each pathway helps to reduce noisy or
variable measurements, leading to a more precise and robust
classifier. Better coverage and quality of human pathway
information is likely to enable more precise prediction of disease
status and, accordingly, better management of patient care. In
addition, human interaction databases are growing exponentially
at present, enabling further opportunities for unveiling novel
functional pathways or complexes [40–43]. Integrating known
pathways and novel hypotheses from protein networks with
Table 1. Frequently selected pathway markers for lung cancer prognosis.
Pathway Name Frequency # genes
a CORGs
From Michigan to Boston
Glutamine up-regulated genes 433/500 5/313 NP LDHA BZW1 TUBA1 LAMB3
Gluconeogenesis 247/500 2/32 LDHA ENO2
Glycolysis
b 245/500 3/22 ENO2 PGK1 ALDOA
Breast cancer estrogen signaling 203/500 3/101 VEGF KRT18 KRT19
Glycolysis and gluconeogenesis 176/500 5/55 GAPD LDHA ENO2 ALDH3B2 ALDH3B1
Estrogen receptor modulators down-regulated genes 138/500 4/74 ARHE STC1 KRT7 COPEB
Leucine down-regulated genes 134.500 4/180 NP LDHA TUBA1 CCNA2
B lymphocyte pathway 102/500 4/11 CR2 ITGAL HLA-DRA CR1
From Boston to Michigan
Breast cancer estrogen signaling 481/500 6/101 KRT18 KRT19 GAPD MT3 CDKN2A TFF1
Pyrimidine metabolism 258/500 3/45 POLR2E NP RRM1
Glycolysis 258/500 2/22 ENO2 PGK1
MTA3 pathway 238/500 3/16 TUBA1 GAPD MTA1
Insulin up-regulated genes 165/500 10/235 PGAM1 ARF4 ARCN1 DNCL1 EIF2S2 PSMA6 YWHAH PSMA3 ZNF9
CLNS1A
P53 hypoxia pathway 148/500 3/20 FHL2 IGFBP3 HIF1A
Glutamine down-regulated genes 133/500 4/313 PGAM1 ERH PAICS BZW1
p53 signalling 114/500 6/101 HIF1A FADD GAPD APEX1 CDKN2A CSNK2B
Estrogen receptor modulators down-regulated genes 108/500 3/74 KRT7 DUSP4 MMD
NFKB up-regulated genes 103/500 2/111 KRT7 GBP1
aThe number of CORGs and member genes are specified.
bPathways/Genes in italics are shared between datasets.
doi:10.1371/journal.pcbi.1000217.t001
Figure 4. Pathway activity of the top frequently used markers in the two lung cancer datasets. Activities were inferred from CORGs
identified from each dataset. Green/red blocks indicate pathways (rows) that are up-/down- regulated in patients (columns) of specific prognosis
(above color bars: pink and green indicate poor and good prognosis, respectively). Pathways are clustered based on the similarity of their activities
across patients.
doi:10.1371/journal.pcbi.1000217.g004
Pathway-Based Disease Classification
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effective molecular characterization of human disease [17].
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indicate metastasis and non-metastasis, respectively). Pathways are
clustered based on the similarity of their activities across patients.
Found at: doi:10.1371/journal.pcbi.1000217.s006 (0.11 MB PDF)
Figure S5 Distribution of numbers of CORGs in top 10%
pathways
Found at: doi:10.1371/journal.pcbi.1000217.s007 (0.01 MB PDF)
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